喀麦隆及时接种乙肝疫苗出生剂量后乙肝病毒母婴传播的残余风险(ANRS 12303):单中心纵向观察性研究
在喀麦隆Tokombéré地区医院对2009-2016年HBsAg阳性母亲所生子女进行前瞻性随访,评估出生剂量乙肝疫苗接种后的母婴传播残余风险。共纳入607名有随访血清学调查的儿童,出生后24小时内接种者HBsAg阳性率为5.6%。结论认为尽管及时接种出生剂量疫苗,母婴传播风险仍相当大。
要点
- 出生后24小时内接种乙肝疫苗的儿童HBsAg阳性率为5.6%。
- 39名感染儿童中35名(89.7%)的母亲为HBeAg阳性且HBV DNA≥5.3 log10 IU/mL。
- 感染母婴配对的全基因组测序证实高一致性(99.97-100%)。
核心结论
- 尽管在出生后24小时内及时接种乙肝疫苗出生剂量,仍记录到相当大的母婴传播风险。
- 为达到WHO消除目标,非洲部分地区除提高乙肝疫苗出生剂量覆盖外,可能还需要围产期抗病毒预防。
研究设计与样本
- 单中心纵向观察性研究,在喀麦隆Tokombéré地区医院系统筛查孕妇HBsAg。
- 当前分析共纳入607名有随访血清学调查的儿童。
主要发现
- 2009年1月31日至2016年12月31日,33309名孕妇中22243名(66.8%)接受产前HBV筛查,其中3901名(17.5%)HBsAg阳性。
- 3901名HBsAg阳性母亲所生子女中2004名(51.4%)接受乙肝疫苗出生剂量,其中1800名(89.8%)完成三剂五价疫苗。
- 出生后24小时内接种出生剂量疫苗的儿童HBsAg阳性率为5.6%,24-47小时接种者为7.0%,48-96小时接种者为16.7%(ptrend=0.083)。
- 39名感染儿童中35名(89.7%)的母亲为HBeAg阳性且HBV DNA≥5.3 log10 IU/mL。
- 感染母婴配对HBV全基因组测序确认一致性比例为99.97-100%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In sub-Saharan Africa, administration of hepatitis B virus (HBV) birth-dose vaccines remains suboptimal. Evidence is scarce on whether African countries should focus on increasing vaccine coverage or developing strategies incorporating additional measures, such as peripartum antiviral prophylaxis to pregnant women at high risk. To better inform decision makers, we estimated the residual risk of mother-to-child transmission despite HBV birth-dose vaccine in Cameroon. METHODS: We did a single-centre, longitudinal observational study. Pregnant women were systematically screened for HBV surface antigen (HBsAg) at Tokombéré District Hospital (Tokombéré district, Cameroon). Children born to HBsAg-positive mothers in 2009-16 who received the HBV birth-dose vaccine and three subsequent doses of pentavalent vaccine at 6, 10, and 14 weeks were followed up prospectively in 2015-17. In children, capillary blood was obtained for HBsAg rapid test and dried blood spots to quantify HBV DNA concentrations. Venous blood was also collected from HBsAg-positive children. Mother-to-child transmission was confirmed by whole-genome sequencing. FINDINGS: Between Jan 31, 2009, and Dec 31, 2016, 22 243 (66·8%) of 33 309 pregnant women accepted antenatal HBV screening, of whom 3901 (17·5%) were HBsAg positive. 2004 (51·4%) of 3901 children who were born to HBsAg-positive mothers received the HBV birth-dose vaccine, of whom 1800 (89·8%) also completed the three-dose pentavalent vaccine. In total, the current analysis included 607 children who had a follow-up serosurvey. The prevalence of HBsAg was 5·6% in children who received the birth-dose vaccine in less than 24 h, 7·0% in those who received it 24-47 h after birth, and 16·7% in those who received it 48-96 h after birth (ptrend=0·083). 35 (89·7%) of 39 infected children were born to mothers positive for HBV e antigen with high HBV DNA of 5·3 log10 IU/mL or more. Whole-genome sequencing of HBV in infected mother-child pairs confirmed high identity proportions of 99·97-100%. INTERPRETATION: We documented a substantial risk of mother-to-child transmission despite timely administration of the HBV birth-dose vaccine within 24 h after birth. To reach WHO's elimination targets, peripartum antiviral prophylaxis might be required in parts of Africa, in addition to increasing coverage of the HBV birth-dose vaccine. FUNDING: Agence nationale de recherches sur le sida et les hépatites virales (ANRS).
引用
- Shimakawa Y, Veillon P, Birguel J, et al. Residual risk of mother-to-child transmission of hepatitis B virus infection despite timely birth-dose vaccination in Cameroon (ANRS 12303): a single-centre, longitudinal observational study. Lancet Glob Health. 2022. PMID: 35183302. doi:10.1016/S2214-109X(22)00026-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。